Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: <i>Radiology</i> In Training.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34060939.
- Also identified by DOI 10.1148/radiol.2021210044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 66-year-old male patient with end-stage chronic kidney disease undergoing maintenance dialysis and with a history of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clinical and pathologic findings consistent with nephrogenic systemic fibrosis. A summary of the evidence and recommendations for use of intravenous GBCM in patients with kidney disease is presented. © RSNA, 2021.
Medical subject headings
- Contrast Media
- Gadolinium DTPA
- Kidney Failure, Chronic
- Nephrogenic Fibrosing Dermopathy